CytoMed Therapeutics Ltd
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
34
Stocks News & Analysis
stocks
Is this ASX share a value trap or bargain?
stocks
Goldman Sachs Earnings: Valuations remain stretched
stocks
Major ASX listed miners overvalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,143.30 | 15.00 | -0.16% |
| CAC 40 | 8,112.02 | 146.92 | -1.78% |
| DAX 40 | 24,959.06 | 338.07 | -1.34% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,195.35 | 39.94 | -0.39% |
| HKSE | 26,552.57 | 11.33 | -0.04% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 52,984.25 | 599.32 | -1.12% |
| NZX 50 Index | 13,545.09 | 35.20 | -0.26% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,822.10 | 14.50 | -0.16% |
| SSE Composite Index | 4,101.62 | 12.38 | -0.30% |